We performed a prospective/retrospective study of a cohort of CRC patients treated with capecitabine-containing regimens in order to evaluate possible associations between severe ADRs to capecitabine and genomic variations in CDA, ABCB1, ENOSF1, TYMS, and MTHFR. Here, TYMS is linked to colorectal carcinoma.